Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease but occurs in people who drink little or no alcohol, and is a highly progressed form of non-alcoholic fatty liver disease (NAFLD). NASH is becoming increasingly common with the alarming epidemic of obesity and carries the risk for more aggressive liver diseases such as cirrhosis, liver failure, and in some rare instances, hepatocellular cancer.
Therapeutic options for NASH are currently very limited, with Vitamin E being the standard of care for patients. This leaves significant unmet need for the disease and, coupled with high disease prevalence in developed countries, results in enticing opportunities for drug developers. As such, there is a very active pipeline for NASH, and many new products are expected to launch over the next 10 years. However, there is still uncertainty over how the NASH treatment landscape will develop as these new products launch.
Key Questions Answered
The NASH market is poised to undergo rapid expansion during the forecast period and beyond. What are the main drivers of this expansion?
What are the main unmet needs in NASH? Will the drugs under development fulfil these needs?
Which patients are the most likely to receive drug treatment for NASH during the forecast period, and which patients are unlikely to be reimbursed?
Scope
GlobalData’s Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026 consists of a slide deck detailing key market-impacting events that have occurred since GlobalData’s previous NASH report publication, along with an updated Excel-based forecasting model which reflects the projected influence of these events on the future NASH market.
The Key Events covered in this NASH Dynamic Market Forecast include:
• Increased Understanding of Potential Treatment Algorithms for NASH Patients With Cirrhosis.
• First Publication of Efficacy Data for Several Phase II NASH Drugs.
• Development of Combination Therapies for NASH.
• Publication of New Phase II Efficacy Data Shifts Competitive Landscape for NASH Pipeline.
Components of the slide deck include:
• Timeline of market-impacting events
• Key clinical trial landscape updates
• Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
• Overview of updates to the forecast model based on anticipated future impact of events
• Forward-looking events calendar listing expected key updates to the NASH competitive space through September 2019
Other events included in the analysis include:
• Regulatory filings
• Approval decisions
• Pricing changes
• Patent litigation
• Clinical trial data announcements
• Clinical trial failures
• Clinical trial timeline updates
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global NASH therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NASH therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Cirius Therapeutics
Conatus Pharma
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead Sciences
Immuron
Intercept Pharmaceuticals
Inventiva
Madrigal Pharmaceuticals
Mitsubishi Tanabe
NGM Bio
Novartis
Novo Nordisk
Viking Therapeutics
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.